Benchmark Lowers Harvard Bioscience (NASDAQ:HBIO) Price Target to $4.50
Harvard Bioscience (NASDAQ:HBIO – Free Report) had its price objective reduced by Benchmark from $5.50 to $4.50 in a report issued on Monday morning,Benzinga reports. They currently have a speculative buy rating on the medical instruments supplier’s stock. Harvard Bioscience Price Performance Shares of NASDAQ:HBIO opened at $0.60 on Monday. Harvard Bioscience has a fifty-two […]
More Stories
First Hawaiian Bank Purchases 60 Shares of AbbVie Inc. $ABBV
First Hawaiian Bank boosted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.8% in the second...
NBC Securities Inc. Sells 405 Shares of Philip Morris International Inc. $PM
NBC Securities Inc. trimmed its position in shares of Philip Morris International Inc. (NYSE:PM – Free Report) by 5.9% during...
Mortgage Refinance Applications Soar Amid Falling Interest Rates
By Andrew Moran The U.S. mortgage market experienced significant activity last week as interest rates declined to a one-year low,...
US Offers $5 Million Reward for Information Leading to Arrest of Sinaloa Cartel Faction Boss
By Chris Summers U.S. authorities on Sept. 16 announced a reward of up to $5 million for information leading to the...
Lionel Messi powers Inter Miami to victory over Seattle Sounders in heated MLS rematch
By Agence France – Presse MIAMI, Florida — Lionel Messi scored one goal and set up another to spark Inter Miami over the...
Gradient Investments LLC Boosts Stake in International Business Machines Corporation $IBM
Gradient Investments LLC lifted its holdings in International Business Machines Corporation (NYSE:IBM – Free Report) by 29.8% in the 2nd...